Browse the evidence

Conjugated equine estrogen (CEE) reduces the risk of hip fractures in postmenopausal women with prior hysterectomy.

CEE reduces hip fracture risk, which is a benefit for bone health. However, because it increases stroke risk and does not prevent heart disease, it is not recommended solely for disease prevention.

Global age-standardized diabetes prevalence has increased or remained unchanged in every country since 1980, with no country showing a statistically significant decrease.

Diabetes risk is rising globally, driven by aging populations and increasing obesity, particularly in low- and middle-income countries. While you cannot change your genetics or age, focusing on maintaining a healthy weight and engaging in regular physical activity are critical strategies to mitigate your personal risk, as these are the primary modifiable drivers identified in the global trends.

Lifelong genetic reduction of LDL cholesterol via PCSK9 sequence variations significantly reduces the incidence of coronary heart disease, with protection persisting despite high prevalence of non-lipid-related cardiovascular risk factors.

Your genetic makeup can influence your cholesterol, but the most powerful thing you can do for your heart health is to keep your LDL levels low throughout your entire life, not just when you get older. This study shows that maintaining low LDL from a young age offers superior protection against heart disease, even if you have other risk factors like high blood pressure or diabetes. Focus on lifelong management of lipid levels rather than waiting for symptoms or later years to intervene.

An intensive lifestyle intervention focused on weight loss through caloric restriction and increased physical activity does not reduce the rate of major cardiovascular events in overweight or obese adults with type 2 diabetes compared to diabetes support and education.

For people with type 2 diabetes, focusing solely on weight loss through diet and exercise may not be enough to prevent heart attacks or strokes, even if it improves blood pressure and blood sugar. While lifestyle changes are beneficial for overall health and quality of life, they should not be relied upon as the sole strategy for cardiovascular protection in this population without considering other medical interventions.

Increased expression of Monocyte Chemoattractant Protein-1 (MCP-1) in adipose tissue directly causes macrophage infiltration, insulin resistance, and hepatic steatosis in obesity.

This research identifies MCP-1 as a key link between fat tissue and insulin resistance. While this is a mouse study, it suggests that therapies targeting MCP-1 or its receptor (CCR2) could potentially treat insulin resistance and fatty liver in obese humans by reducing fat tissue inflammation.

Particulate matter air pollution is the leading contributor to global disease burden, accounting for 8.0% of total DALYs in 2021.

Air pollution is the leading risk factor for global disease burden. Reducing exposure is crucial for long-term health.

Long-term supplementation with beta carotene (50 mg on alternate days) provides no benefit and causes no significant harm regarding the incidence of malignant neoplasms, cardiovascular disease, or all-cause mortality in healthy, well-nourished men.

Do not take beta carotene supplements to prevent cancer or heart disease. This study of over 22,000 men followed for 12 years shows that taking 50 mg of beta carotene every other day does not reduce your risk of cancer, heart disease, or death compared to taking a placebo. While eating fruits and vegetables rich in beta carotene is beneficial, the isolated supplement offers no such protection.

The metabolic syndrome is an imprecise and clinically unhelpful diagnostic construct for predicting cardiovascular disease risk because its definition is ambiguous, its underlying pathophysiology is uncertain, and it offers no predictive advantage over treating individual risk factors.

Do not wait for a 'metabolic syndrome' diagnosis to manage your heart health. If you have high blood pressure, high blood sugar, or abnormal cholesterol, treat those specific issues directly. The concept of 'metabolic syndrome' is too vague and does not add value to standard risk assessment. Focus on controlling your individual risk factors through lifestyle and medication as prescribed, rather than worrying about meeting a specific syndrome threshold.

Combined estrogen plus progestin hormone therapy does not prevent coronary heart disease and increases the risk of CHD, particularly during the first year of use.

Do not use estrogen plus progestin to prevent heart disease. For postmenopausal women with an intact uterus, this combination increases the risk of coronary heart disease, especially in the first year of use. It should not be prescribed for cardiovascular prevention.

Global obesity prevalence has increased significantly and now exceeds underweight prevalence in the vast majority of countries, creating a 'double burden' of malnutrition driven by rising obesity rather than persistent undernutrition.

Focus on healthy nutrition transitions that enhance access to nutritious foods. Address the remaining burden of underweight while curbing and reversing the increase in obesity.

Endogenous GLP-1 is primarily secreted by intestinal L-cells in response to nutrient contact, not by pancreatic alpha-cells.

Your body naturally produces GLP-1 from your intestines when you eat. This hormone helps regulate blood sugar and appetite. Dietary fiber and nutrients stimulate this natural release.

Native GLP-1 has a very short half-life (1-2 minutes) due to rapid degradation by the enzyme DPP-4, necessitating biochemically modified agonists for clinical use.

Your body breaks down natural GLP-1 very quickly. Medications like Ozempic or Wegovy are chemically modified to resist this breakdown, allowing them to work for days instead of minutes.

Daily supplementation with 2000 IU of vitamin D3 does not reduce the incidence of invasive cancer or major cardiovascular events in adults aged 50+ (men) and 55+ (women) compared to placebo.

Taking 2000 IU of vitamin D3 daily will not prevent cancer or heart attacks in generally healthy older adults, according to this major study. While vitamin D is essential for bone health, this specific dose does not offer the broad disease-prevention benefits often marketed. Focus on proven strategies for cancer and heart health prevention rather than relying on this supplement for those outcomes.

Vitamin D3 supplementation (2000 IU/day) does not reduce all-cause mortality in adults aged 50+ (men) and 55+ (women).

Taking 2000 IU of vitamin D3 daily will not help you live longer, based on this study. While it may support bone health, it does not appear to extend lifespan in older adults who are generally healthy.

Cellular senescence is a principle causative factor in organismal aging and facilitates aging-associated diseases.

This mechanism explains why aging tissues accumulate damage. Interventions targeting senescent cells (senolytics) are being researched to mitigate age-related diseases, though specific protocols are not detailed in this text.

Obesity-induced insulin resistance is mechanistically driven by the activation of serine/threonine kinases (such as JNK, IKK, and PKC isoforms) which phosphorylate insulin receptor substrates (IRS) on inhibitory serine residues, thereby blocking normal tyrosine phosphorylation and signal transduction.

Insulin resistance in obesity is not just 'bad luck'; it is a specific biological response to stressors like excess lipids and inflammation. These stressors trigger specific enzymes (kinases) that physically block insulin's ability to signal. Understanding this means recognizing that reducing these stressors (via weight loss, exercise, or metabolic health improvements) can reverse the signaling block.

Genetic mutations in the insulin receptor gene cause rare, severe forms of insulin resistance (e.g., leprechaunism), but these mutations are not observed in routine type-2 diabetes.

Unlike rare genetic disorders, common type-2 diabetes is not caused by broken insulin receptor genes. It is a functional problem of how cells respond to insulin, driven by lifestyle and metabolic factors.

FFAR3 (GPR41) is dispensable for normal body weight, adiposity, and glucose homeostasis in mice, and is not required for the obesity-protective effects of butyrate and propionate.

The receptor FFAR3 (GPR41) is not required for maintaining normal body weight, fat levels, or blood sugar control in mice. This suggests that other mechanisms can compensate for its absence, and that therapies targeting FFAR3 might not be strictly necessary for basic metabolic health.

SGLT2 inhibitors (empagliflozin, dapagliflozin, canagliflozin) reduce cardiovascular mortality, overall mortality, and heart failure hospitalizations in patients with type 2 diabetes and established cardiovascular disease, independent of glycemic control.

If you have type 2 diabetes and existing heart disease, SGLT2 inhibitors (like empagliflozin, dapagliflozin, or canagliflozin) are now recommended not just for blood sugar, but to significantly lower your risk of heart failure, heart attack, stroke, and death. This benefit exists even if your blood sugar control doesn't change much, suggesting the drug protects your heart and kidneys directly.

Senescent cells secrete pro-inflammatory factors (SASP) that drive further senescence in neighboring cells and impair immune function, creating a self-perpetuating cycle of tissue damage.

The accumulation of senescent cells contributes to tissue aging. While senolytics (drugs that clear senescent cells) are in development, current practical steps involve supporting the body's natural clearance mechanisms through healthy lifestyle habits that reduce cellular stress.

Extrinsic morphogen gradients (Wnt, Shh, BMP) play a critical role in patterning the somite and regulating the expression of key myogenic transcription factors (MyoD, Myf5) during embryonic development.

Embryonic muscle development is heavily influenced by environmental signals (morphogens) that guide cell fate. This highlights the complexity of muscle biology, though direct application to adult training is limited.

Activation of the NLRP3 inflammasome in macrophages leads to the secretion of IL-1β and IL-18, which impair insulin signaling and contribute to beta-cell apoptosis in Type 2 Diabetes.

Chronic inflammation in fat tissue activates specific immune pathways (NLRP3 inflammasome) that release harmful cytokines (IL-1β). These cytokines damage insulin signaling and beta-cells. Addressing inflammation may help protect these cells.

A long-term dietary intervention reducing total fat to 20% of calories and increasing fruits, vegetables, and grains does not significantly reduce the risk of coronary heart disease, stroke, or composite cardiovascular disease in postmenopausal women.

For postmenopausal women, simply switching to a low-fat diet (20% of calories) with more fruits, vegetables, and grains is not enough to prevent heart disease or stroke on its own. While it may slightly improve cholesterol and blood pressure, it does not significantly lower cardiovascular event rates. More targeted interventions focusing on specific risk factors are likely necessary.

Standardized Glycemic Index (GI) measurement requires a minimum of 10 healthy subjects and 2-3 repeated trials of the reference food (glucose) to achieve statistically valid precision.

If you are evaluating a food's Glycemic Index, ensure the data comes from a study with at least 10 healthy participants and uses glucose as a standardized reference. Single-subject or anecdotal GI claims are statistically unreliable.